Wells Fargo Upgrades Cencora (COR) Stock to Overweight, Lifts PT

On June 3, Wells Fargo analysts upgraded Cencora, Inc. (NYSE:COR)’s stock from “Equal Weight” to “Overweight,” increasing the price objective to $337 from the prior target of $274, as reported by The Fly.

A medical researcher conducting tests with a top-of-the-line microscope in a laboratory.

The optimism is backed by a favorable industry environment and reduced exposure to macroeconomic and policy risks. In particular, the analysts cited Cencora, Inc. (NYSE:COR)’s limited exposure to medical tariffs and Most Favored Nations drug pricing policy as factors resulting in a competitive advantage over its peers.

The firm’s estimates are generally “in-line” with consensus. Overall, the analysts believe that the company’s earnings stream is likely to remain relatively stable as compared to its peers. Cencora, Inc. (NYSE:COR) updated its FY 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment and a reduced contribution from the International Healthcare Solutions segment.

The company continues to play an important role in the supply chain, driven by its pharmaceutical distribution footprint and complementary end-to-end services and solutions. Cencora, Inc. (NYSE:COR) expects adjusted diluted EPS to be between $15.70 – $15.95, an increase from the prior range of $15.30 – $15.60. Furthermore, it expects adjusted consolidated operating income growth to be between 13.5% – 15.5%, up from the prior range of 11.5% – 13.5%.

Cencora, Inc. (NYSE:COR) sources and distributes pharmaceutical products.

While we acknowledge the potential of COR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than COR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.